KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 151 filers reported holding KITE PHARMA INC in Q1 2015. The put-call ratio across all filers is 1.21 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $65,925,000 | +72.9% | 366,638 | -0.3% | 0.47% | +64.0% |
| Q2 2017 | $38,119,000 | +30.9% | 367,693 | -0.9% | 0.29% | +27.9% |
| Q1 2017 | $29,124,000 | +66.4% | 371,052 | -5.0% | 0.23% | +48.7% |
| Q4 2016 | $17,506,000 | -15.1% | 390,419 | +5.8% | 0.15% | -20.8% |
| Q3 2016 | $20,611,000 | +11.9% | 368,983 | +0.2% | 0.19% | +7.3% |
| Q2 2016 | $18,418,000 | -45.8% | 368,335 | -50.2% | 0.18% | -44.9% |
| Q1 2016 | $33,967,000 | +49.9% | 739,867 | +101.1% | 0.32% | +39.5% |
| Q4 2015 | $22,666,000 | +9.8% | 367,833 | -0.8% | 0.23% | -10.0% |
| Q3 2015 | $20,639,000 | -9.0% | 370,676 | -0.4% | 0.26% | -0.4% |
| Q2 2015 | $22,689,000 | -22.4% | 372,127 | -26.5% | 0.26% | -22.2% |
| Q1 2015 | $29,220,000 | -30.5% | 506,595 | -30.5% | 0.33% | -33.5% |
| Q4 2014 | $42,057,000 | – | 729,265 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,358,084 | $105,736,000 | 48.63% |
| BAINCO INTERNATIONAL INVESTORS | 1,151,540 | $51,635,000 | 8.76% |
| Coastal Bridge Advisors, LLC | 250,040 | $11,212,000 | 4.36% |
| NEXTHERA CAPITAL LP | 150,000 | $6,726,000 | 3.94% |
| Casdin Capital, LLC | 94,000 | $4,215,000 | 3.48% |
| MENORA MIVTACHIM HOLDINGS LTD. | 1,258,899 | $56,449,000 | 2.90% |
| DIALECTIC CAPITAL MANAGEMENT, LP | 85,000 | $3,812,000 | 2.14% |
| SECTORAL ASSET MANAGEMENT INC | 372,223 | $16,690,000 | 1.85% |
| ARK Investment Management | 97,313 | $4,364,000 | 1.59% |
| BB BIOTECH AG | 800,000 | $35,872,000 | 1.33% |